Enlivex Ltd. reported net income of $1.23 billion and diluted earnings per share of $25.48 for fiscal year 2025, with total treasury and treasury-related derivative assets reaching $2.31 billion. The company attributed much of this profitability to appreciation in its treasury and treasury-related derivative assets, demonstrating the effectiveness of its dual business model. Enlivex ended the fiscal year with total shareholders' equity of approximately $1.93 billion and maintained $30 million in cash, cash equivalents, and short-term investments in digital assets.
The company's dual-engine strategy differentiates it from traditional biotech firms by combining a clinical-stage immunotherapy platform focused on quality longevity therapeutics with a treasury model anchored in the Rain decentralized prediction markets protocol. This structure allows public market investors to gain exposure to emerging prediction markets infrastructure while the company continues advancing clinical development programs aimed at improving healthspan and quality of life. To learn more about Enlivex's treasury strategy and read the full earnings report, visit https://www.benzinga.com.
Enlivex is currently advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. Executive Chairman Shai Novik explained that the clinical engine progresses with Allocetra™ and its potential to restore mobility and independence in aging populations, while the treasury engine establishes exposure to prediction markets infrastructure through the Rain protocol. This capital strategy aligns long-term shareholder value with the growth of decentralized forecasting markets.
The dual-engine approach positions Enlivex to pursue innovation in quality longevity therapeutics while developing an innovative treasury model for a public company, which contributed significantly to the company's strong profitability in 2025 based on unrealized appreciation in treasury and treasury-related derivative assets. This model represents a novel approach to funding biotechnology research and development, potentially creating new pathways for capital formation in the longevity sector while maintaining focus on therapeutic advancements that address age-related health challenges.
